Ask about this productRelated genes to: UCHL1 antibody
- Gene:
- UCHL1 NIH gene
- Name:
- ubiquitin C-terminal hydrolase L1
- Previous symbol:
- PARK5
- Synonyms:
- PGP9.5, Uch-L1
- Chromosome:
- 4p13
- Locus Type:
- gene with protein product
- Date approved:
- 1991-07-15
- Date modifiied:
- 2015-11-13
Related products to: UCHL1 antibody
Related articles to: UCHL1 antibody
- : Patients with mild traumatic brain injury (mTBI) have a small but clinically relevant risk of intracranial injury (ICI), requiring timely detection. Computed tomography (CT) remains the diagnostic gold standard but is costly and exposes patients to ionising radiation. Combining blood-based biomarkers, glial fibrillary acidic protein (GFAP) and ubiquitin carboxy-terminal hydrolase L1 (UCH-L1), with clinical decision rules may allow safe exclusion of ICI without CT, reducing unnecessary imaging, radiation exposure, and resource use. : A systematic review of clinical and economic studies in patients with mTBI was registered in PROSPERO (CRD420251051158). Searches were conducted in January 2025 and updated in May 2025 in MEDLINE, Embase, and the Cochrane Library. The aim was to assess the diagnostic accuracy and economic value of the combination of GFAP and UCH-L1 compared with CT scanning to rule out ICI in both adults and children with mTBI. Where available, studies directly comparing GFAP and UCH-L1 with S100β were also analysed descriptively. The quality of the clinical evidence was assessed with QUADAS-2 and GRADE. Meta-analyses used a bivariate random-effects model, with heterogeneity and sensitivity analyses explored. : Overall, 21 studies were considered in our review. Moderate- to high-quality evidence indicates that GFAP and UCH-L1, when used together with clinical assessment, have very high sensitivity and can reliably rule out ICI in adults with mTBI presenting within 12 h to the emergency department. Evidence for paediatric populations shows promise but remains very limited. Specificity is low, particularly in older adults, which limits the ability to reduce CT use in this high-risk group. Research on age-adjusted cut-offs is ongoing and may help to reduce the proportion of false positive tests without compromising sensitivity. Few studies directly compared GFAP and UCH-L1 with S100β, with slightly higher to equivalent sensitivity for GFAP and UCH-L1. Economic evaluations suggest possible cost savings and reduced CT utilisation, but these analyses rely on assumptions unsupported by robust data and are highly context-dependent. There is a lack of clarity in the included studies regarding whether existing clinical head rules were used to define the study populations (i.e., to determine which patients would be recommended for CT scanning) and, if so, which specific rules were applied. : Evidence shows that GFAP and UCH-L1 can safely exclude ICI in adults with mTBI in whom a CT scan would otherwise be considered based on clinical assessment or decision rules. Nevertheless, real-world evidence and cost-effectiveness data are scarce. Further prospective studies, including paediatric and elderly populations, and integration with clinical decision rules will be informative to ensure optimal use in clinical practice. - Source: PubMed
Publication date: 2026/06/23
San Miguel LorenaJespers VickyRoberfroid Dominique - Performance of currently available prognostic models for predicting incomplete functional recovery following mild traumatic brain injury (mTBI) is only modest. Blood-based biomarkers may improve model performance. In this study we aimed to assess the incremental discriminative value of promising biomarkers reflecting activation of relevant pathophysiological processes (mechanistic markers), interleukin (IL) -6, -8, and -10 (inflammation), free thiols (FTs, oxidative stress), and tryptophan (Trp; kynurenine pathway [KP]), to prognostic models containing pertinent clinical predictors. Established mTBI biomarkers, glial fibrillary acidic protein, ubiquitin carboxy-terminal hydrolase L1 (UCH-L1), and neurofilament light were also included to compare prognostic performance with the less well characterized mechanistic markers. In a prospective longitudinal cohort study (Acute Injury Markers for mild traumatic brain injury), 257 patients with mTBI were recruited. Blood was sampled within 24 h of injury at the emergency department (ED) and again 4-6 weeks later. All participants underwent acute head CT scans. Two models were used as reference models: (1) ED model, including only predictors obtained at the ED, and (2) ED+ model, including additional predictors obtained through symptom questionnaires 2 weeks after injury. The primary outcome was the Glasgow Outcome Scale Extended (GOS-E) at 6 months. The incremental prognostic value of biomarkers, relative to the ED or ED+ model, was assessed via optimism-corrected differences (Δ) in the area under the receiver operating curve (AUC) and Nagelkerke's . Outcome data was available for 208 patients, with 49% having incomplete recovery (GOS-E < 8). Plasma IL-6 was the only individual biomarker to improve ED model performance (ΔAUC 0.039 (95% confidence interval, 0.017, 0.057), and ΔR 4.3% (1.2%, 6.7%), albeit modestly. UCH-L1 was the best-performing established marker (ΔAUC 0.005 [-0.008, 0.027] and ΔR 0.1% [-3.8%, 2.1%]). Combining IL-6 with plasma Trp resulted in the largest ED model improvement (ΔAUC 0.041 [0.021, 0.065], ΔR 4.2% [0.0%, 8.1%]). While individual biomarkers provided negligible improvement to the ED+ model, the combination of IL-6, Trp, and plasma FTs resulted in improved performance of the ED+ model (ΔAUC 0.034 [0.012, 0.055] and ΔR 5.4% [-8.2%, 12.4%]). Blood-based mechanistic markers marginally improve performance of prognostic models for incomplete functional recovery following mTBI. The findings of this study highlight the need for further assessment of mechanistic markers, and especially IL-6, in the context of mTBI prognosis. - Source: PubMed
Publication date: 2026/07/13
Visser Koende Koning Myrthe EJacobs BramBourgonje Arno RChayoua Walidvan Faassen Martijnvan der Ley ClaudeKema Ido Pvan Goor Harryvan der Naalt Joukjevan der Horn Harm J - Colorectal cancer (CRC) is a prevalent malignant tumor with increasing incidence and mortality rates worldwide. Exosomes are secretory vesicles generated by the endosomal system within cells. Previous studies have reported that exosome-related genes (ERGs) are associated with the progression of malignancies. This study investigates the role of ERGs in CRC, evaluates their impact on CRC prognosis, and explores inter-individual differences among CRC patients in different risk groups. - Source: PubMed
Publication date: 2026/07/04
Wang KaisongChen TingyuChen YiqiangZhao JiajingFu RuizhiXu XiaolingSu GenghongChen Shubiao - Timely and accurate diagnosis of mild traumatic brain injury (mTBI) remains challenging in acute care. In the Asia-Pacific (APAC) region, marked heterogeneity in healthcare infrastructure, computed tomography (CT) utilization, and diagnostic pathways underscores the need for practical, standardized approaches to assessment. Blood-based biomarkers, particularly glial fibrillary acidic protein (GFAP) and ubiquitin carboxy-terminal hydrolase L1 (UCH-L1), have shown promising diagnostic performance and have been incorporated into clinical pathways in other regions. However, their role in APAC emergency care workflows has not been systematically addressed. This study aimed to develop expert consensus on the definition, diagnosis, and clinical integration of these biomarkers into mTBI assessment across APAC. - Source: PubMed
Publication date: 2026/07/03
Kuan Win SenVeerasarn KullapatJoseph MathewMusikatavorn KhrongwongChung KongPrasert YodrukZairinal Ramdinal AviesenaCordero Jeremy AShukla DhavalMitra Biswadev - Small cell carcinoma of the uterine cervix (UCSCC) is a rare and aggressive HPV-linked neuroendocrine malignancy with limited therapeutic options and poor prognosis. Through integrative analysis of whole-exome sequencing (WES), single-cell RNA-seq (scRNA-seq), PinpoRNA-HPV, bulk RNA-sequencing, and immunohistochemistry (IHC), we delineated its molecular architecture. Genomic profiling unveiled the dysregulation of 10 core oncogenic pathways and an exceptionally high tumor mutational burden (TMB), along with frequent alterations in DNA repair genes. ScRNA-seq analysis identified nine distinct malignant subclusters characterized by lineage plasticity (ASCL1/NEUROD1/UCHL1) alongside active HPV18 transcription. The tumor microenvironment exhibited a paradoxical immune landscape: dense infiltration of CD8+ T cells and CD163+ tumor-associated macrophages (TAMs) in the complete absence of tumoral PD1/PD-L1 expression. Cell-cell communication analysis revealed that malignant subclusters specifically overexpress CD47, engaging SIRB1 on TAMs and SIRPG on T cells. IHC validation confirmed a CD8+/CD163+/PD-L1-phenotype and demonstrated that transcriptional CD47 enrichment in malignant clones implicated the CD47-SIRB1 axis as the primary immune checkpoint. These findings indicated UCSCC as an HPV-driven, heterogeneous tumor that might employ CD47 as an alternative immune evasion pathway in the absence of PD-L1, providing a strong rationale for exploring CD47 blockade as a novel potentially therapeutic strategy. - Source: PubMed
Publication date: 2026/07/03
Zhang QingxinFu JianjiangZhong LiuyingYang ZiyangWeng CanZhong XinFang ShunLiu ShaoyanCai TonghuiSheng XiujieGao HongyiPeng Juan